Jessica Fye
Stock Analyst at JP Morgan
(4.41)
# 353
Out of 4,983 analysts
203
Total ratings
61.42%
Success rate
14.25%
Average return
Main Sectors:
Stocks Rated by Jessica Fye
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MIRM Mirum Pharmaceuticals | Maintains: Overweight | $53 → $77 | $73.79 | +4.35% | 4 | Sep 12, 2025 | |
| ALKS Alkermes | Maintains: Neutral | $34 → $35 | $27.39 | +27.78% | 7 | Sep 9, 2025 | |
| LEGN Legend Biotech | Maintains: Overweight | $77 → $78 | $34.34 | +127.14% | 3 | Aug 25, 2025 | |
| IONS Ionis Pharmaceuticals | Maintains: Neutral | $48 → $49 | $61.32 | -20.08% | 6 | Aug 25, 2025 | |
| INCY Incyte | Maintains: Neutral | $67 → $73 | $83.90 | -12.99% | 8 | Aug 22, 2025 | |
| INSM Insmed | Maintains: Overweight | $111 → $135 | $144.75 | -6.74% | 9 | Aug 20, 2025 | |
| ASND Ascendis Pharma | Maintains: Overweight | $254 → $260 | $197.24 | +31.82% | 15 | Aug 19, 2025 | |
| HALO Halozyme Therapeutics | Maintains: Neutral | $60 → $63 | $75.85 | -16.94% | 14 | Aug 7, 2025 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Overweight | $348 → $475 | $461.24 | +2.98% | 8 | Aug 6, 2025 | |
| ONC BeOne Medicines AG | Maintains: Overweight | $321 → $345 | $327.20 | +5.44% | 3 | Jul 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $515 → $517 | $391.36 | +32.10% | 9 | Jul 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $108 → $113 | $53.94 | +109.49% | 4 | Jul 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $350 → $330 | $397.97 | -17.08% | 17 | Jul 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $33 → $26 | $24.84 | +4.67% | 13 | May 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $120 → $116 | $99.26 | +16.86% | 12 | May 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $10 → $13 | $7.75 | +67.74% | 6 | May 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $54 → $50 | $33.94 | +47.34% | 5 | Apr 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $29 → $28 | $12.68 | +120.82% | 4 | Apr 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $200 → $209 | $126.54 | +65.17% | 4 | Feb 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $28 → $24 | $13.26 | +81.00% | 5 | Jan 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $30 | $9.75 | +207.85% | 1 | Oct 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $47 → $54 | $34.10 | +58.36% | 5 | Jul 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $6 → $13 | $23.16 | -43.87% | 4 | Mar 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Underweight | n/a | $49.89 | - | 7 | Nov 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Underweight | n/a | $7.83 | - | 2 | Nov 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Neutral | n/a | $2.77 | - | 9 | Nov 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Underweight | n/a | $14.93 | - | 6 | Nov 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $1.46 | - | 2 | Aug 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $22 | $1.51 | +1,356.95% | 1 | Apr 19, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $7 | $1.10 | +536.36% | 2 | Jan 29, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $7.21 | - | 4 | Mar 11, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $8.56 | - | 3 | Feb 28, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $7.45 | - | 1 | Feb 8, 2018 |
Mirum Pharmaceuticals
Sep 12, 2025
Maintains: Overweight
Price Target: $53 → $77
Current: $73.79
Upside: +4.35%
Alkermes
Sep 9, 2025
Maintains: Neutral
Price Target: $34 → $35
Current: $27.39
Upside: +27.78%
Legend Biotech
Aug 25, 2025
Maintains: Overweight
Price Target: $77 → $78
Current: $34.34
Upside: +127.14%
Ionis Pharmaceuticals
Aug 25, 2025
Maintains: Neutral
Price Target: $48 → $49
Current: $61.32
Upside: -20.08%
Incyte
Aug 22, 2025
Maintains: Neutral
Price Target: $67 → $73
Current: $83.90
Upside: -12.99%
Insmed
Aug 20, 2025
Maintains: Overweight
Price Target: $111 → $135
Current: $144.75
Upside: -6.74%
Ascendis Pharma
Aug 19, 2025
Maintains: Overweight
Price Target: $254 → $260
Current: $197.24
Upside: +31.82%
Halozyme Therapeutics
Aug 7, 2025
Maintains: Neutral
Price Target: $60 → $63
Current: $75.85
Upside: -16.94%
Alnylam Pharmaceuticals
Aug 6, 2025
Maintains: Overweight
Price Target: $348 → $475
Current: $461.24
Upside: +2.98%
BeOne Medicines AG
Jul 17, 2025
Maintains: Overweight
Price Target: $321 → $345
Current: $327.20
Upside: +5.44%
Jul 14, 2025
Maintains: Overweight
Price Target: $515 → $517
Current: $391.36
Upside: +32.10%
Jul 14, 2025
Maintains: Overweight
Price Target: $108 → $113
Current: $53.94
Upside: +109.49%
Jul 8, 2025
Maintains: Overweight
Price Target: $350 → $330
Current: $397.97
Upside: -17.08%
May 22, 2025
Maintains: Underweight
Price Target: $33 → $26
Current: $24.84
Upside: +4.67%
May 22, 2025
Maintains: Neutral
Price Target: $120 → $116
Current: $99.26
Upside: +16.86%
May 6, 2025
Maintains: Overweight
Price Target: $10 → $13
Current: $7.75
Upside: +67.74%
Apr 14, 2025
Maintains: Overweight
Price Target: $54 → $50
Current: $33.94
Upside: +47.34%
Apr 10, 2025
Maintains: Neutral
Price Target: $29 → $28
Current: $12.68
Upside: +120.82%
Feb 26, 2025
Maintains: Overweight
Price Target: $200 → $209
Current: $126.54
Upside: +65.17%
Jan 7, 2025
Maintains: Overweight
Price Target: $28 → $24
Current: $13.26
Upside: +81.00%
Oct 8, 2024
Initiates: Overweight
Price Target: $30
Current: $9.75
Upside: +207.85%
Jul 9, 2024
Maintains: Overweight
Price Target: $47 → $54
Current: $34.10
Upside: +58.36%
Mar 26, 2024
Maintains: Neutral
Price Target: $6 → $13
Current: $23.16
Upside: -43.87%
Nov 20, 2023
Reinstates: Underweight
Price Target: n/a
Current: $49.89
Upside: -
Nov 20, 2023
Reinstates: Underweight
Price Target: n/a
Current: $7.83
Upside: -
Nov 20, 2023
Reinstates: Neutral
Price Target: n/a
Current: $2.77
Upside: -
Nov 20, 2023
Reinstates: Underweight
Price Target: n/a
Current: $14.93
Upside: -
Aug 20, 2021
Downgrades: Underweight
Price Target: n/a
Current: $1.46
Upside: -
Apr 19, 2021
Initiates: Overweight
Price Target: $22
Current: $1.51
Upside: +1,356.95%
Jan 29, 2021
Upgrades: Neutral
Price Target: $7
Current: $1.10
Upside: +536.36%
Mar 11, 2019
Downgrades: Underweight
Price Target: n/a
Current: $7.21
Upside: -
Feb 28, 2019
Downgrades: Underweight
Price Target: n/a
Current: $8.56
Upside: -
Feb 8, 2018
Downgrades: Neutral
Price Target: n/a
Current: $7.45
Upside: -